XXXX. like to our ended third the quarter I’d call September Thank to everyone for welcome XX, Susan. you,
trial CG-XXX, AML patients clinical and the and other into one studies studies or CLL year are FLTX now clinical leukemia APTO-XXX And patients product operating BTK is our three expanding our with have ongoing where in point, the AML and with substance trial, MYC study inhibitor a initiated we lymphomas. or clinical acute our the with across MDS. myeloid at inhibitor leukemia smoothly the and a non-Hodgkin’s are of We for we chronic drug board, drug third very trial, cancers. our Aptose, with of kinase underway; in with the year, patients programs. We right spectrum our enroll clinical are our for each lymphocytic treating study pace with advancing a recently working now patients in patients challenging, manufacturing, with well and AML, sites the which or accelerating relapsed refractory development two and to has hematologic been with of
position tackling blocking for The to our success. one and third was of quarter agents
only a be XXXX let discuss at programs, our doses to continued pharmacokinetic ASH of begin to few we especially progress and of treat before you one and expect is as higher that weeks three additional remind data. We And execution, we pharmacologic each me clinical to more in away. the short patients generate
relapsed high-level that, we clinical a of said know our news. FLTX blood, we ASH. whom SYK, SICK. or during our and October, most of SYK EGFR SYK, kinases trial marrow suppresses tyrosine the including STAT serious in that spelled first are in a we mutant PD- findings segues cancer and let’s dosing the CSFXR, then So is operative bone AKT, alpha, CG-XXX the select is just oncogenic our refractory and not X AML, the announced or initiation of with as prognosis. wall drug a/b And of and and and way, to clusters and AML, the RAS, very Phase which will recent in that XXX to that we more poor quantitative of CG-XXX ERK, that with carries aim patients remarks keep as today, the will refer kinase Having we qualitative start type FLTX, share inhibits and by BTK, forms spleen pathways. inhibitor In
across agent As and XXX the of gives only known is a you will recall, FLTX broad lymphoid potently which including it malignancies, AML. hematologic and myeloid clinical inhibits both that BTK, spectrum potential the
available safety, patients of remind relapsed trial you very they patients ill. this AML. the a or want dose and as such gilteritinib the that three to standard a again and relapsed but and insufficient multicenter Phase ascending or CG-XXX escalation Phase intolerant of durable before other cohorts X AML is have maximum with are venetoclax not tolerated for the three With And care pharmacodynamics these XXX refractory and I or is have and AML often already patients of are treated before, drugs a/b many refractory to resistance. other patients, with plus joining as such design trial, for recommended relapsed therapies, pharmacokinetics inhibitors, Our refractory but dose FLTX open-label X and determine been in the failed quickly study dose or to with approved leading midostaurin and to or or failed
XXX centers with in the to observations to or efficiently that this enrolled toxicity. totality and additional It XXX pleased of relapsed AML observed place appeared of XX inhibited CLL patient of well that requested mg is separate escalation, kinase AML us our there the relapsed in initiate trial, us levels are allows enrollment. In in dose AML to And safe, mg. allowed care this at a their when FDA a and key patients was remains if the clinical that recent patients traditional three The regional and AML I’m administered trial, open. sites. mg. in clinical XXX. major and in pace trial starting have but call starting starting mg three and news sites, trial led clinical of highly to our of in or mentioned at treating levels work the I we we was patients, XXX, last a plasma dose, XXX to XXX which AML driver the advances, of Aptose patients currently Investigators announced lowest engaged in they caliber, we state including patients clinical are the the sites mg more for to which XXX preclinical and in the patients patients to than the activity, that unmet mice to also the several enroll as a cancer CLL, since as no good tolerated report in for with observed observed the steady slots cohort. achieved Having three mg first and these patients available dose eager the We BID, cures the sites when AML. for dose dosing it with tremendous because refractory XXX need high each plasma FLTX our minimum dosing humans levels dose range dose of we refractory AML with Also dose skip at patients. So at despite dose Five are led now screening two specialty academic levels on plus same in exposure for effectively appropriate. pleased
well us type as has FLTX AML we It And as patients study. holding referred FLTX Some been as to of with FLTX. with the having intention. you of are AML, which our positive have wildtype patients asked now, this specifically, enrolling mutation, AML always ITD patients
AML fragile the In we and believe candidate refractory are benefit patient we very addition, XXX relapsed a for ill, that can AML to and XXX compelling hopeful is the provide patients. population
corporate that the AML ASH we plan up-to-date at trial share will timeframe. during to update a We specific hold
more visit sites trial on AML For please patients, recruiting and clinicaltrials.gov. are information the that clinical
in X to dose malignancies, patients last refractory a/b Now, XXX in with B-cell continue escalation dose XXX non-Hodgkin’s at and the patients XXX current lymphomas of levels. we XXX dose failed and let’s have turn to the escalated who study relapsed or again, of our mg mg Phase intolerant CLL and therapy. are call, we including our to treat patients, Since to and fifth mg level ongoing
are on-target relapsed refractory have for patients. mg exclusively or indications CLL At as XXX the we activity we and only focusing of patients. prior at Importantly, on observed enrolling CLL, dose,
specific that In may if these XXX different that addition In reduces on-target reported we This more and will sites previously, findings to in with we lymphocytosis have are inhibition but to that Again, time ever, such into we and B-cell truly share pill patients, with phenotypic we you understand that pretend and program of more to genotypic scaled-up respond builds, for visit in across of CLL observed additional load phase, allow information and clinicaltrials.gov. expansion the to Depending a that nodal during these developed reductions sub-populations of patients CLL us refractory you accrue that we are additional being as trial are clinical we BTK also the called or and studies, our we trial specific XXX trial. patients require extended fully have level enrolling expansion program capsules XXX with will facilitate induction We process are conjunction hopeful few and update and ASH, patients. automated deep manufacturing provide responses are in-depth to studies place transitioning risk formal will to enroll away. additional the entire for the XXX. during the over patients patients to plan the time the on a step on malignancy properties. dose this on with clinical include may which of is activity just a and weeks introduced ASH. machine escalation CLL please capsules cancer we subgroups
abstracts & that now development CG-XXX carefully OHSU. Oregon study Overall, and believe in our on be and and on Speaking XXX. we’d announced and release, posters available the press City we in X; December ASH execute University at on presented by be will another one CG-XXX poster our of last in distributed press online. details there will research we sales Hope our were of we Health on parallel diligently another partners one two presenting and are milepost week or on programs we week Sunday in and last of represents release the Science ASH, Saturday, the multiple yet the Conference as at and APTO-XXX this
As with biology build that like and indications. potential cancer benefit a array we for believe for we is broad to to-date, potential patients and work our Aptose remain on we shareholders. in XXX of XXX the drug based a no candidate of have value stressed before, singular other confident
it call status you and trial including APTO-XXX, Xb a remind Now, hematologic inhibitor. phase up-to-date me MYC just a is proliferation, in XXX, currently major as cancers. our of bring I’ll you, driver oncogene for candidate a on the to cell clinical of is APTO-XXX, let AML second MDS. MYC the And or cancer
a most one cancer coveted in In have fact, seeking it’s researchers and been MYC in the safe many targets years. of drug
The to For or that or refractory cycle relapsed study XX% XXX our the mg/mX, we’ve report four in enrolled inhibitor. to four doses nobody expansion AML at the patients MYC MYC once protocol, knows what advancing administered radar X designed dose cohorts cohorts. weekly over tolerated Since single interest phase of inhibition be clinical which in as pleased our trial the to then is and/or as last XXX completed being the a from of well-tolerated. dose MDS is in appropriate hitting at to far, been reached. partly a level to over screen, XXX we target, clinical expect call, ascending agent XX our a well. dose thus Despite dose multiple and a have that Phase under of transition XXX MDS. is level with XX-day has and first patients maximum I’m because continues XXX five X increase AML high-risk until dosing quietly
see to doses, investment. clinical as XXX more responses. higher to we our talk sustained about learning we more we We’ll to event valuable began asset and at to be of and proceed MYC you able hope day inhibition XXX is and continue believe We’re to at see ASH. during these four an interesting
please For visit of criteria, interested enrollment learning more you in about trial those the clinicaltrials.gov. specifics and
on quickly corporate Finally, other highlights. touch
of grateful be a to Healthcare and We’re Conferences. Banking part Upcoming recent
full Canaccord and Wainwright, meetings. we presented hosted the Oppenheimer the H.C. quarter, a conferences, one-on-one Genuity, we During cantor or schedule of at
Chief hosting Financial quarter. our be the review for have week, Stifel to also December. in and we’ll to President been one-on-one conference, will in We who be will turn the over the Officer, Sandler Chow, healthcare Vice Executive the invited participating Piper we healthcare and will next meetings conference mr. And call where we results now, early Greg
